V. Höiom

发表

KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.

L. Kanter‐Lewensohn, J. Hansson, A. Zebary, 2013, Journal of dermatological science.

Genome-wide association study identifies three loci associated with melanoma risk

J. Malvehy, S. Puig, E. Gillanders, 2009, Nature Genetics.

Genome-wide association study identifies three new melanoma susceptibility loci

Jeffrey E. Lee, J. Malvehy, S. Puig, 2011, Nature Genetics.

Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status

H. Olsson, J. Hansson, H. Helgadottir, 2017, Journal of the American Academy of Dermatology.

Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways

David M. Evans, Jeffrey E. Lee, A. Uitterlinden, 2017, bioRxiv.

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

S. Puig, D. Bishop, D. Elder, 2017, The Journal of investigative dermatology.

Whole-Exome Sequencing of Germline Variants in Non-BRCA Families with Hereditary Breast Cancer

S. Mane, C. Larsson, H. Helgadottir, 2022, Biomedicines.

Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families

S. Puig, D. Bishop, D. Elder, 2021, BMC Public Health.

Whole-Exome Sequencing of Germline Variants in Non-BRCA Families with Hereditary Breast Cancer

S. Mane, C. Larsson, H. Helgadottir, 2022, Biomedicines.

Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.

S. Puig, D. Bishop, D. Elder, 2016, The Journal of investigative dermatology.

Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study

D. Schadendorf, S. Puig, J. Barrett, 2012, Pigment cell & melanoma research.

CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015–2020: implications for novel national recommendations

K. Nielsen, J. Lapins, Å. Borg, 2021, Acta oncologica.

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma

T. Helleday, J. Hansson, V. Höiom, 2020, Cell Death & Differentiation.

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma

V. Höiom, Rainer Tuominen, S. Egyházi Brage, 2022, Cancers.

Phenocopies in melanoma-prone families with germ-line CDKN2A mutations

H. Olsson, M. Tucker, A. Goldstein, 2017, Genetics in Medicine.

Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer.

S. Chanock, M. Tucker, N. Freedman, 2022, JCO precision oncology.

Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits

D. Gudbjartsson, A. Sigurdsson, Á. Jónasdóttir, 2008, Nature Genetics.

Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.

S. Puig, N. Hayward, H. Olsson, 2014, The Journal of investigative dermatology.

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types

Paolo Vineis, Giuseppe Matullo, Kari Stefansson, 2009, Nature Genetics.

Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma

Marko Hočevar, Kevin M. Brown, Florence Demenais, 2015, Nature Genetics.

Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility

Blair H. Smith, Jeffrey E. Lee, G. Abecasis, 2020, Nature Genetics.

MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters

J. Lundeberg, J. Hansson, M. Käller, 2009, Pigment cell & melanoma research.

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells

L. Kanter, J. Hansson, J. Lehtiö, 2017, Cell Death and Disease.

A variant in FTO shows association with melanoma risk not due to BMI

Marko Hočevar, Florence Demenais, Kari Stefansson, 2013, Nature Genetics.

Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility

Blair H. Smith, Jeffrey E. Lee, G. Abecasis, 2020, Nature Genetics.

The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility

S. Kjellqvist, P. Engström, D. Edsgärd, 2016, Genes, chromosomes & cancer.

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations

S. Chanock, H. Olsson, M. Yeager, 2016, Human Genetics.

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib

D. Grandér, J. Hansson, R. Fernandes, 2020, Melanoma research.

Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148

Geoffrey S. Tobias, K. Nielsen, J. Malvehy, 2017, Nature Communications.

The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length

Jeffrey E. Lee, S. Puig, E. Gillanders, 2014, Journal of the National Cancer Institute.

Genome‐wide linkage analysis of Swedish families to identify putative susceptibility loci for cutaneous malignant melanoma

J. Hansson, V. Höiom, Rainer Tuominen, 2011, Genes, chromosomes & cancer.

The Application of Clinical Genetics Dovepress the Genetics of Uveal Melanoma: Current Insights

H. Helgadottir, V. Höiom, Veronica Höiom, 2022 .

Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide

Ivana K. Kim, S. Puig, N. Hayward, 2018, Journal of the National Cancer Institute.

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors

P. Ascierto, H. Eriksson, H. Helgadottir, 2022, Cancers.

Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy

F. Edfors, M. Uhlén, L. Fagerberg, 2021, Cancer Research.

An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study

D. Schadendorf, S. Puig, J. Barrett, 2013, Pigment cell & melanoma research.

New common variants affecting susceptibility to basal cell carcinoma

D. Gudbjartsson, A. Sigurdsson, T. Blondal, 2009, Nature Genetics.

Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma.

M. Tucker, A. Goldstein, J. Lundeberg, 2021, Genetics in medicine : official journal of the American College of Medical Genetics.

Investigation of a putative melanoma susceptibility locus at chromosome 3q29.

H. Olsson, C. Ingvar, G. Jönsson, 2014, Cancer genetics.

IRF4 variants have age-specific effects on nevus count and predispose to melanoma.

Nicole Soranzo, Johan Hansson, Nicholas G Martin, 2010, American journal of human genetics.

Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study

S. Puig, E. Gillanders, D. Elder, 2010, Journal of the National Cancer Institute.

Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma

J. Hansson, H. Gréen, S. Vikingsson, 2017, Analytical and Bioanalytical Chemistry.

A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma

L. Kanter, J. Hansson, H. Johansson, 2021, Acta oncologica.

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families

Å. Borg, H. Olsson, C. Ingvar, 2014, Journal of Medical Genetics.

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

S. Puig, H. Olsson, M. Lauss, 2018, Journal of Medical Genetics.

CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe

H. Olsson, O. Dekkers, C. V. van Asperen, 2018, Journal of Medical Genetics.

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

K. Nielsen, H. Olsson, G. Jönsson, 2016, Journal of the National Cancer Institute.

CDKN2a mutation‐negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies

Johan Hansson, Göran Jönsson, H. Olsson, 2015, International journal of cancer.

Hereditary uveal melanoma: A report of a germline mutation in BAP1

O. Emanuelsson, J. Lundeberg, D. Edsgärd, 2013, Genes, chromosomes & cancer.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.

K. Brown, G. Mann, N. Hayward, 2019, Melanoma research.

Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia

S. Puig, D. Elder, N. Hayward, 2021, Genetics in Medicine.

Inherited variation in the PARP1 gene and survival from melanoma

Dirk Schadendorf, Susana Puig, Johan Hansson, 2014, International journal of cancer.

Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study

J. Lapins, H. Olsson, C. Ingvar, 2020, Journal of the National Cancer Institute.

Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions

S. Puig, E. Gillanders, K. Brown, 2014, International journal of cancer.

Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.

S. Puig, D. Bishop, D. Elder, 2019, Journal of the American Academy of Dermatology.

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status

M. Wilhelm, J. Hansson, V. Höiom, 2019, Cell Death & Disease.

BAP1 genetic testing among melanoma and cancer-prone families in Sweden

J. Lapins, H. Helgadottir, I. Vassilaki, 2023, Acta oncologica.

Novel high risk genes of melanoma

N. Hayward, D. Adams, P. Johansson, 2017 .

The Application of Clinical Genetics Dovepress the Genetics of Uveal Melanoma: Current Insights

H. Helgadottir, V. Höiom, 2022 .

Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways

David M. Evans, A. Uitterlinden, T. Spector, 2017, Nature Communications.

The Application of Clinical Genetics Dovepress the Genetics of Uveal Melanoma: Current Insights

H. Helgadottir, V. Höiom, 2022 .

Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma

D. Schadendorf, S. Puig, E. Gillanders, 2015, Nature Genetics.

Familial features affecting the melanoma risk in CDKN2A-negative melanoma families: a study based on the Swedish Cancer Registry

H. Helgadottir, V. Höiom, Karina Schultz, 2023, Acta oncologica.

The Application of Clinical Genetics Dovepress the Genetics of Uveal Melanoma: Current Insights

H. Helgadottir, V. Höiom, 2022 .

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

K. Nielsen, H. Olsson, G. Jönsson, 2016, Journal of the National Cancer Institute.